These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33567441)

  • 1. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
    Sejben A; Vörös A; Golan A; Zombori T; Cserni G
    Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
    Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
    Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
    Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
    Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
    Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
    Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
    Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
    Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
    Mod Pathol; 2024 Jul; 37(7):100517. PubMed ID: 38763422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
    Tozbikian GH; Zynger DL
    Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.
    Zombori T; Cserni G
    Pathol Oncol Res; 2018 Apr; 24(2):259-267. PubMed ID: 28470571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of SOX10 and GATA3 in mammary carcinoma.
    Qazi MS; McGregor SM
    Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer.
    Klaric KA; Riaz N; Asleh K; Wang XQ; Atalla T; Strickland S; Nielsen TO; Kos Z
    Histopathology; 2022 Feb; 80(3):589-597. PubMed ID: 34725848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
    Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
    Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-100 protein and SOX10-positive breast carcinoma mimicking metastatic melanoma.
    Newman J; Brahmbhatt M; Stoff BK; Martinez AP
    J Cutan Pathol; 2020 Dec; 47(12):1187-1191. PubMed ID: 32710508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.
    Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM
    Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
    Na K; Woo HY; DO SI; Kim SW
    In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers.
    Davion SM; Siziopikou KP; Sullivan ME
    Histopathology; 2012 Oct; 61(4):660-6. PubMed ID: 22748158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.